XJPX
4061
Market cap2.09bUSD
Jul 10, Last price
3,913.00JPY
1D
-0.15%
1Q
2.68%
Jan 2017
51.67%
Name
Denka Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Denka Company Limited, an enterprise based in Tokyo, Japan, and established in 1915, operates as a global producer and purveyor of a diverse range of organic and inorganic materials. Its extensive product portfolio caters primarily to the electronics and pharmaceutical sectors. The company's operations are segmented into several key divisions. The Electronics & Innovative Products segment is dedicated to developing and supplying advanced components such as conductive agents crucial for lithium-ion batteries, along with thermal management materials, specialized substrates, high-performance ceramics, and various films and tapes. Under its Life Innovation division, Denka plays a significant role in public health, offering influenza vaccines, producing rapid diagnostic kits – including those for identifying novel coronavirus antigens – and providing macromolecular sodium hyaluronate preparations. The Elastomers & Infrastructure Solutions arm encompasses a variety of products, ranging from specialized functional elastomers and cement additives to agricultural essentials like fertilizers and corrugated pipes. Finally, the Polymer Solutions division focuses on synthetic materials, featuring styrene-based resins, food packaging sheets, and synthetic fibers utilized in wigs and hairpieces, alongside poval and other diverse chemical offerings. Originally founded in 1915 as Denki Kagaku Kogyo Kabushiki Kaisha, the company adopted its current name, Denka Company Limited, in October 2015.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||